Organic Thiophosphate Antiretroviral Agents

Published date: Feb. 1, 2012

Technology description

Summary

The current technology represents a potentially safe and effective addition to the antiretroviral drug combinations used for treatment of HIV infection. Amifostine, phosphonol and functional derivatives thereof are available for licensing and commercial development for use as antiretroviral drugs. These organic thiophosphate reducing agents inhibit HIV viral growth and protein expression in HIV-infected human white blood cells without destroying the cells. The compounds described in this technology block growth of HIV by a mechanism that is dependent on the level of aminothiol reducing agent in the cellular environment. In addition, a range of effective doses and methods for oral administration of the available organic thiophosphates is provided.
Market:
Nearly 40.3 million people living with HIV worldwide, including approximately 2.0 million people in North America and Europe
Anti-HIV/AIDS therapeutics experience accelerated market acceptance and draw revenues of approximately $240 million to $1 billion

Application area

Novel therapeutics for the treatment of HIV infection
Safe and effective addition to the drug combinations currently used to treat HIV/AIDS

Institution

NIH - National Institutes of Health

联系我们

叶先生

电 话：021-65679356

手 机：13414935137

邮 箱：yeyingsheng@zf-ym.com